Literature DB >> 22434104

RAMPs and CGRP receptors.

James Barwell1, Denise Wootten, John Simms, Debbie L Hay, David R Poyner.   

Abstract

Receptor activity modifying protein 1 (RAMP1) forms a complex with calcitonin receptor-like receptor (CLR) to produce the receptor for calcitonin gene-related peptide (CGRP). RAMP1 has two main roles. It facilitates the cell-surface expression of CLR. It is also essential for the binding of CGRP to the receptor. It seems likely that Y66, F93, H97 and F101, amongst other residues, form a binding site for CLR. These cluster together on the same face of the extracellular portion of RAMP1, probably close to where it enters the plasma membrane. Residues at the other end of RAMP1 are most likely to be involved in CGRP recognition, although it is currently unclear how they do this. Within this area, W74 is important for the binding of the nonpeptide antagonist, BIBN4096BS, although it does not seem to be involved in the binding of CGRP itself. It has been shown that there is an epitope within residues 23-60 of CLR that are essential for RAMP recognition. Under some circumstances, changes in the expression of RAMP1 can alter the sensitivity of cells to CGRP, demonstrating that regulation of its levels may be of physiological or pathophysiological importance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434104     DOI: 10.1007/978-1-4614-2364-5_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

Review 1.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 2.  Migraine in the era of precision medicine.

Authors:  Lv-Ming Zhang; Zhao Dong; Sheng-Yuan Yu
Journal:  Ann Transl Med       Date:  2016-03

Review 3.  Anti-CGRP monoclonal antibodies in migraine: current perspectives.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Martina Curto; Andrea Negro; Raffaele Costantini; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2016-06-23       Impact factor: 3.397

4.  Soluble fms-like tyrosine kinase-1 and angiotensin2 target calcitonin gene-related peptide family peptides in maternal vascular smooth muscle cells in pregnancy†.

Authors:  Madhu Chauhan; Ancizar Betancourt; Meena Balakrishnan; Akansha Mishra; Karin Fox; Michael Belfort; Chandra Yallampalli
Journal:  Biol Reprod       Date:  2021-05-07       Impact factor: 4.285

Review 5.  Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Francesco Cipollone; Paolo Martelletti; Raffaele Costantini
Journal:  J Pain Res       Date:  2017-12-08       Impact factor: 3.133

6.  Oligomeric Receptor Complexes and Their Allosteric Receptor-Receptor Interactions in the Plasma Membrane Represent a New Biological Principle for Integration of Signals in the CNS.

Authors:  Dasiel O Borroto-Escuela; Kjell Fuxe
Journal:  Front Mol Neurosci       Date:  2019-09-25       Impact factor: 5.639

7.  Serum Calcitonin Gene-Related Peptide and Receptor Protein Levels in Patients With Fibromyalgia Syndrome: A Cross-Sectional Study.

Authors:  Ragıp Ulvi Korucu; Ahmet Karadağ; Ayça Taş; Esma Özmen; Emrullah Hayta; Yavuz Siliğ
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

8.  The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story.

Authors:  D Cervia; G Casini
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

9.  DNA methylation of RAMP1 gene in migraine: an exploratory analysis.

Authors:  Dongjun Wan; Lei Hou; Xiaofei Zhang; Xun Han; Min Chen; Wenjing Tang; Ruozhuo Liu; Zhao Dong; Shengyuan Yu
Journal:  J Headache Pain       Date:  2015-10-26       Impact factor: 7.277

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.